APBI 2016

Who decides? Low risk:  the same in NL, UK, B, It, D, …? • Countries with 5 y endocrine therapy for ALL ER+ •  Countries with endocrine therapy starting at intermediate risk (≥ 5% recurrence or survival benefit) • Side effects: • Very (too?) well documented and known for RT • Emerging knowledge for systemic therapy… RT after tumorectomy: not always required? Less local treatment: where is the limit?